NRG 200 Pharmacology for Human Caring Nursing Midterm
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions - 169 Questions with Answers
NRG 200 Pharmacology for Human Caring Nursing Midterm Exam 2026-169 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation document for NRG 200 Pharmacology for Human
Caring Nursing contains 200 verified questions and answers, meticulously aligned with the 2026/2027
academic year curriculum. Each question is accompanied by a correct answer and a detailed rationale,
ensuring a deep understanding of pharmacological principles within the context of human caring
nursing. The content is organized by key content areas, reflecting the latest guidelines and best
practices in nursing pharmacology. This resource is designed to facilitate effective study and mastery
of essential concepts, promoting success on the midterm examination.
Key Features:
Pharmacokinetics and Pharmacodynamics
Drug Classifications and Mechanisms of Action
Nursing Implications and Patient Education
Safe Medication Administration and Dosage Calculations
Adverse Effects, Interactions, and Contraindications
Human Caring Theory Integration in Pharmacology
Updates for 2026:
- Updated to reflect 2026/2027 NCLEX-RN test plan changes
- Revised to incorporate latest FDA drug approvals and safety alerts
- Enhanced rationales with evidence-based practice references
- Expanded coverage of high-alert medications and black box warnings
- Aligned with current human caring nursing frameworks
Abstract:
This exam preparation document for NRG 200 Pharmacology for Human Caring Nursing is a scholarly resource
designed to support nursing students in achieving mastery of pharmacological concepts essential for safe and
compassionate patient care. The 200 questions are carefully selected to represent the breadth and depth of the
midterm curriculum, encompassing foundational principles of drug therapy, major drug classifications, and the
integration of human caring theory into pharmacological interventions. Each question includes a verified correct
answer and a comprehensive rationale that explains the underlying pharmacological mechanisms, nursing
considerations, and potential clinical implications. The content is organized into logical content areas, allowing
for focused study and self-assessment. This document serves as an invaluable tool for exam preparation,
reinforcing critical thinking and clinical reasoning skills necessary for success in nursing practice. By engaging
with these materials, students will enhance their ability to apply pharmacological knowledge in a caring and
patient-centered manner, ultimately improving patient outcomes.
Keywords:
NRG 200, Pharmacology, Human Caring Nursing, Midterm Exam, Verified Questions, Nursing Pharmacology,
Exam Prep, 2026-2027
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer clearly indicated. A detailed
rationale is provided for each answer, explaining the pharmacological basis, nursing implications, and why the
Page 1
,other options are incorrect. This format promotes active learning and reinforces key concepts.
Compliance Checklist:
All questions align with the NRG 200 course objectives and midterm exam blueprint.
Answers are verified for accuracy based on current pharmacological standards and guidelines.
Rationales are evidence-based and reference reputable sources.
Content is updated to reflect the 2026/2027 academic year and latest nursing practice standards.
The document is formatted for easy navigation and self-study.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Autonomic Nervous System 31-60 Cholinergics, Anticholinergics, Adrenergics, 15%
Drugs Adrenergic Blockers
Cardiovascular and Renal Drugs 61-90 Antihypertensives, Diuretics, Cardiac 15%
Glycosides, Antiarrhythmics,
Anticoagulants
Central Nervous System Drugs 91-120 Sedatives-Hypnotics, Antidepressants, 15%
Antipsychotics, Anticonvulsants, Opioids
Endocrine and Metabolic Drugs 121-150 Insulin, Oral Hypoglycemics, Thyroid 15%
Hormones, Corticosteroids, Sex Hormones
Antimicrobial and 151-180 Antibiotics, Antivirals, Antifungals, 15%
Anti-inflammatory Drugs NSAIDs, DMARDs
Nursing Implications and 181-200 Patient Education, Medication Safety, 10%
Human Caring Integration Cultural Considerations, Ethical Issues
Page 2
,Q1. A patient on long-term phenytoin therapy presents with ataxia, nystagmus, and
elevated plasma concentration. Which pharmacokinetic principle best explains the
need for careful dose titration in this scenario?
A. First-order kinetics with linear clearance
B. Zero-order kinetics at therapeutic concentrations
C. Saturable protein binding leading to increased free fraction
D. Autoinduction of hepatic enzymes requiring dose escalation
Correct Answer: B. Zero-order kinetics at therapeutic concentrations
Rationale: Phenytoin exhibits saturable (Michaelis-Menten) metabolism, meaning at
therapeutic concentrations, small dose increases cause disproportionate rises in plasma
levels, leading to toxicity. This zero-order kinetics pattern requires cautious titration and
monitoring.
Why Wrong:
A - First-order kinetics would show proportional dose-response, not the sudden
toxicity seen.
C - Phenytoin is highly protein-bound, but saturation of binding sites is not the
primary cause of dose-dependent toxicity.
D - Phenytoin does cause enzyme induction, but that would lower levels, not cause
toxicity.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36.
Q2. A patient with severe hypertension and heart failure is prescribed a beta-blocker.
Which concurrent condition would be a contraindication, and what is the underlying
pharmacological rationale?
A. Asthma; beta-2 blockade causes bronchoconstriction
B. Hyperthyroidism; beta-blockade masks tachycardia
C. Migraine; beta-blockers are not effective for prophylaxis
D. Glaucoma; beta-blockers increase intraocular pressure
Correct Answer: A. Asthma; beta-2 blockade causes bronchoconstriction
Rationale: Non-selective beta-blockers block beta-2 receptors in bronchial smooth muscle,
precipitating bronchospasm. Thus, asthma is a contraindication. Selective beta-1 blockers
are preferred but can still pose risk at high doses.
Why Wrong:
B - Beta-blockers are used in hyperthyroidism to control symptoms; it's not a
contraindication.
C - Beta-blockers are actually used for migraine prophylaxis, so this is incorrect.
D - Beta-blockers reduce intraocular pressure and are used for glaucoma, not a
contraindication.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 18.
Q3. A patient on warfarin develops a supratherapeutic INR of 5.2 without bleeding.
Which vitamin K-related mechanism explains the appropriate management?
A. Vitamin K directly inactivates warfarin in the bloodstream
B. Vitamin K is a cofactor for clotting factor synthesis, and warfarin inhibits its
recycling
C. High-dose vitamin K promotes rapid hepatic metabolism of warfarin
D. Vitamin K enhances renal excretion of warfarin metabolites
Correct Answer: B. Vitamin K is a cofactor for clotting factor synthesis, and warfarin
inhibits its recycling
Rationale: Warfarin inhibits vitamin K epoxide reductase, reducing regeneration of active
vitamin K, which is needed for gamma-carboxylation of clotting factors II, VII, IX, X.
Administration of vitamin K bypasses this block, allowing synthesis of active factors, thus
lowering INR.
Why Wrong:
A - Vitamin K does not directly interact with warfarin molecules.
C - Vitamin K does not increase warfarin metabolism; it overcomes the
pharmacodynamic effect.
D - Renal excretion is not the mechanism; vitamin K acts on clotting factor synthesis
in the liver.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34.
Q4. A patient with type 2 diabetes has chronic kidney disease (eGFR 25 mL/min) and
is prescribed metformin. Which pharmacodynamic/pharmacokinetic consideration is
most critical?
A. Metformin is contraindicated due to risk of lactic acidosis
B. Metformin requires dose adjustment based on liver function
C. Metformin increases insulin secretion, risking hypoglycemia
D. Metformin is safe because it does not undergo renal excretion
Correct Answer: A. Metformin is contraindicated due to risk of lactic acidosis
Rationale: Metformin is primarily excreted unchanged by the kidneys. In severe renal
impairment (eGFR <30 mL/min), accumulation increases the risk of lactic acidosis, a
life-threatening adverse effect. Therefore, it is contraindicated.
Why Wrong:
B - Metformin is not hepatically metabolized; renal function is the key.
C - Metformin does not increase insulin secretion; it improves insulin sensitivity and
reduces hepatic glucose production.
D - Metformin is excreted renally, so renal impairment is a major concern.
Page 4
Exam Prep Document | 2026/2027 Edition | 200 Verified
Questions - 169 Questions with Answers
NRG 200 Pharmacology for Human Caring Nursing Midterm Exam 2026-169 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation document for NRG 200 Pharmacology for Human
Caring Nursing contains 200 verified questions and answers, meticulously aligned with the 2026/2027
academic year curriculum. Each question is accompanied by a correct answer and a detailed rationale,
ensuring a deep understanding of pharmacological principles within the context of human caring
nursing. The content is organized by key content areas, reflecting the latest guidelines and best
practices in nursing pharmacology. This resource is designed to facilitate effective study and mastery
of essential concepts, promoting success on the midterm examination.
Key Features:
Pharmacokinetics and Pharmacodynamics
Drug Classifications and Mechanisms of Action
Nursing Implications and Patient Education
Safe Medication Administration and Dosage Calculations
Adverse Effects, Interactions, and Contraindications
Human Caring Theory Integration in Pharmacology
Updates for 2026:
- Updated to reflect 2026/2027 NCLEX-RN test plan changes
- Revised to incorporate latest FDA drug approvals and safety alerts
- Enhanced rationales with evidence-based practice references
- Expanded coverage of high-alert medications and black box warnings
- Aligned with current human caring nursing frameworks
Abstract:
This exam preparation document for NRG 200 Pharmacology for Human Caring Nursing is a scholarly resource
designed to support nursing students in achieving mastery of pharmacological concepts essential for safe and
compassionate patient care. The 200 questions are carefully selected to represent the breadth and depth of the
midterm curriculum, encompassing foundational principles of drug therapy, major drug classifications, and the
integration of human caring theory into pharmacological interventions. Each question includes a verified correct
answer and a comprehensive rationale that explains the underlying pharmacological mechanisms, nursing
considerations, and potential clinical implications. The content is organized into logical content areas, allowing
for focused study and self-assessment. This document serves as an invaluable tool for exam preparation,
reinforcing critical thinking and clinical reasoning skills necessary for success in nursing practice. By engaging
with these materials, students will enhance their ability to apply pharmacological knowledge in a caring and
patient-centered manner, ultimately improving patient outcomes.
Keywords:
NRG 200, Pharmacology, Human Caring Nursing, Midterm Exam, Verified Questions, Nursing Pharmacology,
Exam Prep, 2026-2027
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer clearly indicated. A detailed
rationale is provided for each answer, explaining the pharmacological basis, nursing implications, and why the
Page 1
,other options are incorrect. This format promotes active learning and reinforces key concepts.
Compliance Checklist:
All questions align with the NRG 200 course objectives and midterm exam blueprint.
Answers are verified for accuracy based on current pharmacological standards and guidelines.
Rationales are evidence-based and reference reputable sources.
Content is updated to reflect the 2026/2027 academic year and latest nursing practice standards.
The document is formatted for easy navigation and self-study.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Autonomic Nervous System 31-60 Cholinergics, Anticholinergics, Adrenergics, 15%
Drugs Adrenergic Blockers
Cardiovascular and Renal Drugs 61-90 Antihypertensives, Diuretics, Cardiac 15%
Glycosides, Antiarrhythmics,
Anticoagulants
Central Nervous System Drugs 91-120 Sedatives-Hypnotics, Antidepressants, 15%
Antipsychotics, Anticonvulsants, Opioids
Endocrine and Metabolic Drugs 121-150 Insulin, Oral Hypoglycemics, Thyroid 15%
Hormones, Corticosteroids, Sex Hormones
Antimicrobial and 151-180 Antibiotics, Antivirals, Antifungals, 15%
Anti-inflammatory Drugs NSAIDs, DMARDs
Nursing Implications and 181-200 Patient Education, Medication Safety, 10%
Human Caring Integration Cultural Considerations, Ethical Issues
Page 2
,Q1. A patient on long-term phenytoin therapy presents with ataxia, nystagmus, and
elevated plasma concentration. Which pharmacokinetic principle best explains the
need for careful dose titration in this scenario?
A. First-order kinetics with linear clearance
B. Zero-order kinetics at therapeutic concentrations
C. Saturable protein binding leading to increased free fraction
D. Autoinduction of hepatic enzymes requiring dose escalation
Correct Answer: B. Zero-order kinetics at therapeutic concentrations
Rationale: Phenytoin exhibits saturable (Michaelis-Menten) metabolism, meaning at
therapeutic concentrations, small dose increases cause disproportionate rises in plasma
levels, leading to toxicity. This zero-order kinetics pattern requires cautious titration and
monitoring.
Why Wrong:
A - First-order kinetics would show proportional dose-response, not the sudden
toxicity seen.
C - Phenytoin is highly protein-bound, but saturation of binding sites is not the
primary cause of dose-dependent toxicity.
D - Phenytoin does cause enzyme induction, but that would lower levels, not cause
toxicity.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36.
Q2. A patient with severe hypertension and heart failure is prescribed a beta-blocker.
Which concurrent condition would be a contraindication, and what is the underlying
pharmacological rationale?
A. Asthma; beta-2 blockade causes bronchoconstriction
B. Hyperthyroidism; beta-blockade masks tachycardia
C. Migraine; beta-blockers are not effective for prophylaxis
D. Glaucoma; beta-blockers increase intraocular pressure
Correct Answer: A. Asthma; beta-2 blockade causes bronchoconstriction
Rationale: Non-selective beta-blockers block beta-2 receptors in bronchial smooth muscle,
precipitating bronchospasm. Thus, asthma is a contraindication. Selective beta-1 blockers
are preferred but can still pose risk at high doses.
Why Wrong:
B - Beta-blockers are used in hyperthyroidism to control symptoms; it's not a
contraindication.
C - Beta-blockers are actually used for migraine prophylaxis, so this is incorrect.
D - Beta-blockers reduce intraocular pressure and are used for glaucoma, not a
contraindication.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 18.
Q3. A patient on warfarin develops a supratherapeutic INR of 5.2 without bleeding.
Which vitamin K-related mechanism explains the appropriate management?
A. Vitamin K directly inactivates warfarin in the bloodstream
B. Vitamin K is a cofactor for clotting factor synthesis, and warfarin inhibits its
recycling
C. High-dose vitamin K promotes rapid hepatic metabolism of warfarin
D. Vitamin K enhances renal excretion of warfarin metabolites
Correct Answer: B. Vitamin K is a cofactor for clotting factor synthesis, and warfarin
inhibits its recycling
Rationale: Warfarin inhibits vitamin K epoxide reductase, reducing regeneration of active
vitamin K, which is needed for gamma-carboxylation of clotting factors II, VII, IX, X.
Administration of vitamin K bypasses this block, allowing synthesis of active factors, thus
lowering INR.
Why Wrong:
A - Vitamin K does not directly interact with warfarin molecules.
C - Vitamin K does not increase warfarin metabolism; it overcomes the
pharmacodynamic effect.
D - Renal excretion is not the mechanism; vitamin K acts on clotting factor synthesis
in the liver.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34.
Q4. A patient with type 2 diabetes has chronic kidney disease (eGFR 25 mL/min) and
is prescribed metformin. Which pharmacodynamic/pharmacokinetic consideration is
most critical?
A. Metformin is contraindicated due to risk of lactic acidosis
B. Metformin requires dose adjustment based on liver function
C. Metformin increases insulin secretion, risking hypoglycemia
D. Metformin is safe because it does not undergo renal excretion
Correct Answer: A. Metformin is contraindicated due to risk of lactic acidosis
Rationale: Metformin is primarily excreted unchanged by the kidneys. In severe renal
impairment (eGFR <30 mL/min), accumulation increases the risk of lactic acidosis, a
life-threatening adverse effect. Therefore, it is contraindicated.
Why Wrong:
B - Metformin is not hepatically metabolized; renal function is the key.
C - Metformin does not increase insulin secretion; it improves insulin sensitivity and
reduces hepatic glucose production.
D - Metformin is excreted renally, so renal impairment is a major concern.
Page 4
